Adverse Events Associated with Radium-223: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization

被引：0
|
作者：
Huynh-Le, M. P. [1 ]
Shults, R. C. [1 ]
Connor, M. [1 ]
Hattangadi-Gluth, J. A. [1 ]
机构：
[1] Univ Calif San Diego, La Jolla, CA 92093 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2019年 / 105卷 / 01期
关键词：
D O I：
10.1016/j.ijrobp.2019.06.1315
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3298
引用
收藏
页码：E562 / E562
页数：1
相关论文
共 50 条
  • [1] Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization
    Minh-Phuong Huynh-Le
    Shults, Randall C.
    Connor, Michael J.
    Hattangadi-Gluth, Jona A.
    CLINICAL GENITOURINARY CANCER, 2020, 18 (03) : 192 - +
  • [2] Fosfomycin-associated adverse events: A disproportionality analysis of the FDA Adverse Event Reporting System
    Yang, Luxuan
    Zhang, Wenyong
    Shen, Xiujuan
    Liu, Meiqin
    Wu, Meiying
    Xiao, Dan
    DRUG DISCOVERIES AND THERAPEUTICS, 2025,
  • [3] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Zou, Shu-peng
    Yang, Hai-yun
    Ouyang, Meng-ling
    Cheng, Qian
    Shi, Xuan
    Sun, Ming-hui
    BMC PHARMACOLOGY & TOXICOLOGY, 2023, 24 (01):
  • [4] Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Xiong, Xiaomei
    Zhang, Xiuwen
    Li, Xiaoxia
    Huang, Taomin
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (11) : 1447 - 1452
  • [5] Analysis of Unusual Adverse Effects After Radium-223 Dichloride Administration
    Frantellizzi, Viviana
    Pontico, Mariano
    Pani, Arianna
    Pani, Roberto
    De Vincentis, Giuseppe
    CURRENT RADIOPHARMACEUTICALS, 2020, 13 (02) : 159 - 163
  • [6] Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
    Shu, Yamin
    Ding, Yiling
    Liu, Lulu
    Zhang, Qilin
    CNS NEUROSCIENCE & THERAPEUTICS, 2023, 29 (09) : 2705 - 2716
  • [7] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Shu-peng Zou
    Hai-yun Yang
    Meng-ling Ouyang
    Qian Cheng
    Xuan Shi
    Ming-hui Sun
    BMC Pharmacology and Toxicology, 24
  • [8] A disproportionality analysis of adverse events associated with loop diuretics in the FDA Adverse Event Reporting System (FAERS)
    Xue, Zehu
    Liu, Xi
    Liu, Qifeng
    Yang, Xiuming
    Yu, Lixia
    BMC PHARMACOLOGY & TOXICOLOGY, 2025, 26 (01):
  • [9] Cardiovascular adverse events associated with parp inhibitors: A disproportionality analysis of FDA adverse event reporting system
    Viswam, Subeesh Kulangara
    Kheterpal, Aarushi
    Dhas, Ashwin
    Zeba, Zeba
    Shettigar, Amrutha
    Lukose, Lipin
    Kaur, Gursimran
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 452 - 452
  • [10] Adverse events related to radium-223 treatment: "real-life" data from the Eudra-Vigilance database
    Tema, Giorgia
    Lombardo, Riccardo
    Voglino, Olivia
    Sica, Angela
    Baldassarri, Valeria
    Nacchia, Antonio
    Iacovelli, Roberto
    Tubaro, Andrea
    De Nunzio, Cosimo
    MINERVA UROLOGY AND NEPHROLOGY, 2021, 73 (03): : 342 - 348
12345